Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wormwood
- Development stage
- Phase 2
- Lead developer
- University of Freiburg
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Wormwood (Artemisia absinthium) is a perennial herb traditionally used for digestive disorders and recently investigated for its immunomodulatory properties in inflammatory bowel disease (IBD). In clinical trials for Crohn's disease, wormwood has demonstrated a significant steroid-sparing effect, allowing patients to taper off corticosteroids while maintaining or achieving clinical remission. Its mechanism of action is thought to involve the suppression of pro-inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), and it has also been observed to improve mood and quality of life in patients, potentially through its effects on the gut-brain axis.
- Other names
- Artemisia absinthiumcommon wormwoodabsinthe
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on wormwood.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wormwood.